Cotherix chose Access TCA over three competitors to design and build a new exhibit to announce the approval of an inhaled form of Ventavis® (iloprost) for treating pulmonary arterial hypertension.
The exhibit occupies a 20’x20′ space and features a unique oversized three-dimensional alveoli structure designed to visually depict the impact of blood flow constriction on the alveoli–both with and without treatment. Over 20′ tall, the structure is a magnet for attention and a catalyst for sparking conversations.
Throughout the development process, collaboration was essential, as it involved not only the client’s brand team but also their partnered agency, Stratagem Healthcare Communications.
PB Communications 